The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic malignancies.
 
Paulo Gustavo Bergerot
No Relationships to Disclose
 
Rebecca A. Nelson
No Relationships to Disclose
 
Da-Wei Ye
No Relationships to Disclose
 
Petros Grivas
Honoraria - Myriad Genetics
Consulting or Advisory Role - Dendreon; Genentech; Myriad Genetics
Research Funding - Bayer (Inst); Genentech/Roche (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst)
 
Parminder Singh
No Relationships to Disclose
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
Other Relationship - Exelixis; Medivation; Takeda
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (Inst); GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Aveo; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation